Methods of treating multiple sclerosis (MS) using an IL-17A and IL-17F antagonist
US8268773B2 · kind B2 · utility
10Cited by
13References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 27, 2011 |
| Grant date | Sep 18, 2012 |
| Priority date | — |
| Expiry date | Jan 27, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.